Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure
In This Article:
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Oops, something went wrong
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.